Omalizumab (Xolair®), a humanized monoclonal antibody against human immunoglobulin E (IgE), was recently approved as an add-on therapy for chronic spontaneous urticaria (csU) refractory to treatment in patients aged 12 years and above. e dose in this indication is 300 mg subcutaneously every 4 weeks. is dose was administered to pa-tients showing an inadequate response despite re peated systemic treatment with H1 and H2 antihis-tamines or leukotriene receptor antagonists. e urticaria activity score over 7 days (UAS7) in this group went down from 31.2 on average to ≤ 6 in 52 % and to 0 in 33 % within a 12-week period